{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:26:33Z","timestamp":1761920793128,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["Intramural"],"award-info":[{"award-number":["Intramural"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Broadly neutralizing monoclonal antibodies (bNAbs) against conserved domains in the influenza hemagglutinin are in clinical trials. Several next generation influenza vaccines designed to elicit such bNAbs are also in clinical development. One of the common features of the isolated bNAbs is the use of restricted IgVH repertoire. More than 80% of stem-targeting bNAbs express IgVH1-69, which may indicate genetic constraints on the evolution of such antibodies. In the current study, we evaluated a panel of influenza virus bNAbs in comparison with HIV-1 MAb 4E10 and anti-RSV MAb Palivizumab (approved for human use) for autoreactivity using 30 normal human tissues microarray and human protein (&gt;9000) arrays. We found that several human bNAbs (CR6261, CR9114, and F2603) reacted with human tissues, especially with pituitary gland tissue. Importantly, protein array analysis identified high-affinity interaction of CR6261 with the autoantigen \u201cEnhancer of mRNA decapping 3 homolog\u201d (EDC3), which was not previously described. Moreover, EDC3 competed with hemagglutinin for binding to bNAb CR6261. These autoreactivity findings underscores the need for careful evaluation of such bNAbs for therapeutics and stem-based vaccines against influenza virus.<\/jats:p>","DOI":"10.3390\/v12101140","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T08:52:41Z","timestamp":1602147161000},"page":"1140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Autoreactivity of Broadly Neutralizing Influenza Human Antibodies to Human Tissues and Human Proteins"],"prefix":"10.3390","volume":"12","author":[{"given":"Surender","family":"Khurana","sequence":"first","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Hahn","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Klenow","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Golding","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14760584.2017.1299576","article-title":"Strategies to induce broadly protective antibody responses to viral glycoproteins","volume":"16","author":"Krammer","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1473-3099(19)30393-7","article-title":"Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: Interim results of a randomised, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Bernstein","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Khurana, S. (2018). Development and regulation of novel influenza virus vaccines: A United States young scientist perspective. Vaccines, 6.","DOI":"10.3390\/vaccines6020024"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1073\/pnas.1218256109","article-title":"Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody","volume":"110","author":"Schmidt","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"316ra192","DOI":"10.1126\/scitranslmed.aad0522","article-title":"Immune history profoundly affects broadly protective B cell responses to influenza","volume":"7","author":"Andrews","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1038\/s41598-019-40175-8","article-title":"Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies","volume":"9","author":"Bajic","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1128\/MCB.00761-08","article-title":"Crystal structure of human Edc3 and its functional implications","volume":"28","author":"Ling","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nprot.2009.3","article-title":"Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen","volume":"4","author":"Smith","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L.L., Alard, P., Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., and Guan, Y. (2008). Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003942"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1084\/jem.20121977","article-title":"Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies","volume":"210","author":"Yang","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/imr.12363","article-title":"TRIM21: A cytosolic Fc receptor with broad antibody isotype specificity","volume":"268","author":"Foss","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1016\/j.vaccine.2016.08.057","article-title":"Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications","volume":"34","author":"Sparrow","year":"2016","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature11371","article-title":"Structural and genetic basis for development of broadly neutralizing influenza antibodies","volume":"489","author":"Lingwood","year":"2012","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.immuni.2019.09.001","article-title":"Germline-encoded affinity for cognate antigen enables vaccine amplification of a human broadly neutralizing response against influenza virus","volume":"51","author":"Sangesland","year":"2019","journal-title":"Immunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1128\/JVI.02378-14","article-title":"Polyreactivity and autoreactivity among HIV-1 antibodies","volume":"89","author":"Liu","year":"2015","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.immuni.2017.11.023","article-title":"Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens","volume":"48","author":"Abbott","year":"2018","journal-title":"Immunity"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/10\/1140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:17:21Z","timestamp":1760177841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/10\/1140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["v12101140"],"URL":"https:\/\/doi.org\/10.3390\/v12101140","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2020,10,8]]}}}